CPChengjie Pu

Chengjie Pu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chengjie Pu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Haijun Che

    College of Pharmacy, Chengdu Airport Campus, Southwest Minzu University, Chengdu 610041, China

    1 shared publication
  • Honghao Liu

    School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin 150001, China

    1 shared publication
  • Jiawei Wu

    The Architectural Design and Research Institute of Zhejiang University Co. Ltd., 148 Tianmushan Rd., Hangzhou 310058, China

    1 shared publication
  • Jinyue Lv

    Computational Biology Research Center, School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China

    1 shared publication
  • Mengyan Zhang

    Computational Biology Research Center, School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China

    1 shared publication
  • Yan Zhang

    School of Life Science and Technology, Faculty of Life Sciences and Medicine, Harbin Institute of Technology, Harbin, China

    1 shared publication

Latest Publications

  • Open Access

    Developing CuS for Predicting Aggressiveness and Prognosis in Lung Adenocarcinoma

    by Honghao Liu, Haijun Che, Mengyan Zhang, Jinyue Lv, Chengjie Pu, Jiawei Wu, Yan Zhang, Yue Gu

    Cuproptosis is a newfound cell death form that depends on copper (Cu) ionophores to transport Cu into cancer cells. Studies on the relationship have covered most common cancer types and analyzed the links between cuproptosis-related genes (CRGs) and various aspects of tumor characteristics. In this study, we evaluated the role of cuproptosis in lung adenocarcinoma (LUAD) and constructed the cuproptosis-related score (CuS) to predict aggressiveness and prognosis in LUAD, so as to achieve precise treatment for patients. CuS had a better predictive performance than cuproptosis genes, possibly due to the synergy of SLC family genes, and patients with a high CuS had a poor prognosis. Functional enrichment analysis revealed the correlation between CuS and immune and mitochondrial pathways in multiple datasets. Furthermore, we predicted six potential drugs targeting high-CuS patients, including AZD3759, which is a targeted drug for LUAD. In conclusion, cuproptosis is involved in LUAD aggressiveness, and CuS can accurately predict the prognosis of patients. These findings provide a basis for precise treatment of patients with high CuS in LUAD.